DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2326419/alnylam-alny-amvuttra-givlaari-fuel-revenues-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-2326419 Aug 23, 2024 - Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns. 0

https://www.fool.com/investing/2024/08/18/2-unstoppable-healthcare-stocks-to-buy-right-now/?source=iedfolrf0000001 Aug 18, 2024 - These companies' growth paths should only be briefly interrupted by headwinds. 0

https://www.zacks.com/stock/news/2323425/incyte-incy-announces-data-on-monjuvi-fda-approval-for-gvhd-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323425 Aug 16, 2024 - Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease. 0

https://seekingalpha.com/news/4140530-bristol-myers-novartis-slam-medicare-prices-key-drugs?source=feed_sector_healthcare Aug 15, 2024 - Bristol Myers Squibb (BMY) and Novartis (NVS) criticize the U.S. government as Medicare announces revised prices for their blockbuster therapies. Read more here. 0

https://www.zacks.com/stock/news/2319903/pharma-stock-roundup-lly-nvo-bayry-q2-earnings-mrk-s-new-deal-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2319903 Aug 09, 2024 - Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo. 0

https://www.zacks.com/stock/news/2315373/alnylam-alny-up-as-q2-earnings-beat-on-collaboration-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2315373 Aug 02, 2024 - Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales. 0

https://seekingalpha.com/article/4707449-koninklijke-bam-groep-nv-kbagf-q2-2024-earnings-call-transcript?source=feed_sector_transcripts Jul 27, 2024 - Koninklijke BAM Groep nv (OTCPK:KBAGF) Q2 2024 Earnings Call Transcript July 25, 2024 4:00 AM ETCompany ParticipantsMichel Aupers - IR ManagerRuud Joosten -... 0

https://seekingalpha.com/article/4707331-nv-bekaert-sa-beksf-q2-2024-earnings-call-transcript?source=feed_sector_transcripts Jul 26, 2024 - NV Bekaert SA (OTCPK:BEKSF) Q2 2024 Results Conference Call July 24, 2024 4:00 AM ETCompany ParticipantsGuy Marks - Investor RelationsYves Kerstens - Chief... 0

https://seekingalpha.com/news/4127796-novartis-to-collaborate-with-dren-bio-on-bispecific-antibody-therapies?source=feed_sector_healthcare Jul 24, 2024 - Novartis (NVS) has entered into a collaboration with Dren Bio for the discovery and development of bispecific antibody therapies for the treatment of cancer. Read more here. 0

https://www.zacks.com/stock/news/2305396/ionis-ions-completes-enrolment-for-rare-disease-drug-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2305396 Jul 19, 2024 - Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year. 0